摘要
目的研究抑癌基因PTEN在骨肉瘤组织中的表达及其临床意义。方法应用免疫组织化学SP法检测PTEN在38例骨肉瘤组织及20例骨软骨瘤中的表达。结果骨肉瘤组PTEN蛋白阳性表达率63.2%(24/38),显著低于骨软骨瘤组的85.0%(17/20)(P<0.01);骨肉瘤高中分化组PTEN蛋白阳性表达率71.4%(15/21).显著高于低分化组的52.9%(9/17),差异有统计学意义(P<0.01)。PTEN蛋白阳性表达率与患者年龄、性别、肿瘤组织大小、部位无关(P>0.05)。结论抑癌基因PTEN在骨肉瘤的发生、发展中起重要作用,对其蛋白的检测可作为判定骨肉瘤发生及预后的一项客观指标。
Objective To investigate the expression of tumor supresssr gene PTEN in osteosarcoma and study its clinical-pathological implication and its clinical significance. Methods The expression of PTEN were detected by immunohistochemistry SP method in 38 cases of osteosarcoma,20 of osteochondroma. Results 63.2 percent(24 of 38) of cases had expression of PTEN in the tumor cells,and 85 percent of cases(17 of 20) of the osteochondroma it were present. There was a significant positive correlation between osteosarcoma and osteochondmma(P 〈0.01). The positive rates of PTEN in high and middle degrees of differentiation were significantly higher than that in low degree of differentiation(71.4 % vs 52.9 % ). PTEN protein expression had no relation to the patients' age,sex,tumor size and location(P 〉 0.05). Conclusion PTEN gene plays an important role in the occurrence and development of osteosarcoma. It is suggested that PTEN can be a useful marker for predicting invasion of osteosarcoma.
出处
《中国基层医药》
CAS
2007年第4期537-538,共2页
Chinese Journal of Primary Medicine and Pharmacy